Aclaris Therapeutics, Inc. (ACRS) Operating margin 2017–2025
Aclaris Therapeutics, Inc. (ACRS) operating margin by fiscal year — reported operating income divided by reported revenue.
-975.9%FY2025 · since FY2017: -3230.0% → -975.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -975.9% | -217.7 pp |
| FY2024 | -758.2% | -446.6 pp |
| FY2023 | -311.6% | -9.5 pp |
| FY2022 | -302.0% | +1025.1 pp |
| FY2021 | -1327.1% | -541.6 pp |
| FY2020 | -785.4% | +1841.9 pp |
| FY2019 | -2627.3% | -1249.0 pp |
| FY2018 | -1378.3% | +1851.7 pp |
| FY2017 | -3230.0% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More ACRS financial trends
ACRS RevenueACRS Net incomeACRS Net marginACRS Gross profitACRS Gross marginACRS Operating incomeACRS Operating cash flowACRS Free cash flowACRS Capital expendituresACRS Return on equityACRS Stock buybacksACRS Dividends paidACRS Total assetsACRS Total liabilitiesACRS Shareholders’ equityACRS overview →